Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Jeff Smith, Starboard Value CEO, joins CNBC's 'Squawk on the Street' to discuss how he sees Pfizer going forward, potential ...
Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...
Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...
The activist investor claims Pfizer failed to capitalize on the windfall earned from its COVID-19 vaccine and, in the process, destroyed tens of billions of dollars in market value.
Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...
Pfizer’s situation with activist investor Starboard Value is already getting messy. | After initially supporting a meeting ...
Starboard Value LP Chief Executive Officer Jeffrey Smith said there has been at least $20 billion in value destruction at drugmaker Pfizer Inc., which he admonished for failing to deliver on a ...